Budapest: Europe’s most sweeping rewrite of its medicines law in more than two decades is taking shape, and the makers of generic and biosimilar drugs that fill pharmacy shelves across Hungary and the wider bloc stand among its clearest winners.
At the heart of the pharmaceutical package, agreed in principle late last year and now being finalised, lies a rebalancing of the protections that govern who can sell what, and when. The reform restructures the regulatory exclusivity that shields original medicines from competition, tightening the link between holding an authorisation and actually putting a product on the market. The aim is to stop companies parking approvals they never use while still rewarding genuine innovation.
For the generics industry, concentrated in central Europe and a backbone of countries like Hungary, the most important change is a broadened Bolar exemption. That provision lets rival manufacturers carry out the testing and regulatory groundwork needed to launch a copycat drug before the originator’s protection expires, so cheaper versions can reach patients the moment the legal door opens rather than years later. Widening it shortens the lag between patent cliff and price drop, a shift worth millions to health systems that buy in volume.
The package also confronts a quieter crisis: the collapse of the market for new antibiotics. Drug-resistant infections kill tens of thousands of Europeans a year, yet developing fresh antimicrobials is commercially unrewarding because doctors rightly hoard new drugs to slow resistance, leaving little to sell. The reform answers with transferable exclusivity vouchers, an unusual instrument that grants a developer of a priority antimicrobial one extra year of data protection that can be used on the antibiotic itself or sold and attached to any other centrally authorised medicine. Critics warn the vouchers could prove an expensive way to coax investment, since the bonus year may land on a blockbuster unrelated to infection. Supporters counter that nothing else has moved the needle.
Environmental obligations rise across the board. For any medicine with an antimicrobial action, the risk assessment must now weigh the danger that manufacturing, use and disposal will breed resistance in the environment, and crucially that scrutiny extends along the entire supply chain, including plants outside the bloc where much active ingredient is made.
The reform tries, too, to keep pace with science. New regulatory sandboxes will let developers test personalised therapies, advanced cell and gene treatments, products that lean on artificial intelligence, and experimental approaches such as bacteria-killing phage therapy under flexible supervision, a recognition that yesterday’s rulebook never imagined today’s medicine.
Industry reaction splits along predictable lines. Innovator companies grumble that trimming exclusivity will chill investment and push research elsewhere; generics makers and many health ministries welcome faster competition and lower bills. Patient groups, for their part, care less about the architecture than the outcome: whether the overhaul actually delivers more medicines, sooner, at prices systems can bear. The legislation still needs final sign-off, but its direction, toward faster competition and harder questions for the originators, is now set.
